provisions of paragraphs (10) and (11). (B) Report Once the data and information needed to conduct the study described in subparagraph (A) has become available and the Comptroller General has had sufficient opportunity to review and analyze such data and information, the Comptroller General shall develop and publish a report on the findings of such study, including with respect to the following: (i) Effects on enrollee cost-sharing, utilization and adherence, formulary coverage and placement, and utilization management with respect to affected covered part D drugs (discount-eligible drugs and covered part D drugs for which, prior to implementation of such provisions, cost-sharing exceeded net price for some beneficiaries). (ii) Changes to pharmacy reimbursement methodologies and levels, if any, with respect to discount-eligible drugs. (iii) Changes in manufacturer rebating levels (relative to gross costs) for discount-eligible drugs. (iv) Other behavioral responses by PDP sponsors, enrollees, manufacturers, pharmacies, or other entities related to the implementation of such provisions. (v) Effects of such provisions on enrollee premiums and Federal outlays. (vi) Other issues determined appropriate by the Comptroller General. (C) Subsequent reports The Comptroller General may, as determined appropriate, conduct subsequent studies and produce subsequent reports with respect to the ongoing implementation and effects of the provisions of paragraphs (10) and (11).